Most Read Articles
4 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
3 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
Yesterday
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 3 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Piperacillin-tazobactam inferior to meropenem for E. coli, K. pneumoniae bloodstream infections

Roshini Claire Anthony
22 May 2018

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

“The use of piperacillin-tazobactam as definitive therapy for bloodstream infections caused by E. coli or K. pneumoniae with non-susceptibility to third-generation cephalosporins was inferior to meropenem and should be avoided in this context,” presented study author Dr Patrick Harris from The University of Queensland Centre for Clinical Research in Queensland, Australia at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018).

Of the 1,646 patients screened in this multinational (32 centres in nine countries), open-label, noninferiority trial, 379 adults with bloodstream infections caused by third-generation cephalosporin non-susceptible E. coli or K. pneumonia were randomized within 72 hours of a blood culture collection to receive piperacillin-tazobactam (4.5 g every 6 hours; n=188) or meropenem (1 g every 8 hours; n=191) for ≥4 days.

A majority of the patients were from Singapore (40.6 percent), followed by Australia (22.4 percent) and Turkey (12.1 percent). More than half of the bloodstream infections were healthcare-associated (56.4 percent), were mostly due to E. coli (86.5 percent), and began in the urinary tract (60.9 percent).

At 30 days post-randomization, all-cause mortality was higher among patients who received piperacillin-tazobactam compared with those who received meropenem (12.3 percent vs 3.7 percent, relative risk 3.4, 95 percent confidence interval, 1.5–7.6; p=0.002). [ECCMID 2018, abstract O1121]

Incidence of subsequent infections due to carbapenem-resistant gram-negative organisms or Clostridium difficile was comparable between patients who received piperacillin-tazobactam and meropenem.

“We found quite a significant difference in the primary outcome for mortality,” said Harris. “We were hoping that we would find that these two drugs [piperacillin-tazobactam and meropenem] were equivalent. There has been some observational data over the last few years that suggest that they might be safe and they might be an alternative to carbapenems.”

“Carbapenems are great antibiotics, but over the years there has been increasing use of carbapenems and probably the greatest antibiotic threat that we face at the moment is carbapenem resistance in our common gram-negative [bacteria],” said Harris, highlighting the need for alternatives to reduce reliance on carbapenems for severe infections.

“It is in a way a bit of a disappointing result but it highlights the sort of studies we need to be doing to answer these questions and we really need to try hard to seek these carbapenem-sparing alternatives but test them in a very rigorous way,” he concluded.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
3 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
Yesterday
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 3 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.